Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise their independent medical judgment and to consult with relevant guidelines, expert opinion, and the individual patient's circumstances when making clinical decisions. Drug dosages and treatment protocols may vary based on local guidelines and patient factors. Always verify drug information and contraindications. This reference is not a substitute for professional medical training or direct patient care.

---

ADEM (Acute Disseminated Encephalomyelitis)

Overview

• Definition: Acute disseminated encephalomyelitis (ADEM) is a monophasic, immune-mediated inflammatory and demyelinating disorder of the central nervous system (CNS), typically occurring after an infection or, less commonly, vaccination. It is characterized by acute or subacute multifocal neurological deficits and encephalopathy.
• Epidemiology: ADEM is a rare disorder.
  • Incidence: Estimated at 0.2-0.8 per 100,000 individuals per year.
  • Age: Predominantly affects children, with 75-80% of cases occurring in the pediatric population. The mean age of onset is typically 5-8 years.
  • Seasonality: Often follows seasonal infections, particularly viral infections.
  • Gender: No significant gender predominance has been consistently observed.
• Classification:
  • Post-infectious ADEM: The most common form, developing after a variety of viral (e.g., measles, mumps, rubella, varicella-zoster virus, influenza, Epstein-Barr virus, enteroviruses) or bacterial (e.g., Mycoplasma pneumoniae, Group A Streptococcus) infections.
  • Post-vaccination ADEM: A very rare complication associated with certain vaccines (historically, older rabies or smallpox vaccines; exceedingly rare with modern vaccines).
  • Acute Hemorrhagic Leukoencephalitis (AHLE) (Hurst's disease): A rare, severe, hyperacute, and often fatal variant of ADEM characterized by necrotizing vasculitis and widespread hemorrhages within the CNS white matter.
  • Multiphasic ADEM (MDEM): Defined by a recurrence of ADEM symptoms and new lesions occurring more than 3 months after the initial episode, distinct from the relapsing-remitting course of multiple sclerosis (MS).
  • Biphasic ADEM: Recurrence within 1-3 months with new lesions.
  • MOG-antibody-associated demyelinating disease (MOGAD): While ADEM is a clinical phenotype, a significant proportion of ADEM cases, especially recurrent ones, are now recognized to be associated with antibodies to Myelin Oligodendrocyte Glycoprotein (MOG-IgG). MOGAD is now considered a distinct disease spectrum that can present as ADEM, optic neuritis, or transverse myelitis, and has implications for prognosis and management.

Pathophysiology

• Mechanism: ADEM is considered an autoimmune disorder where the immune system mistakenly attacks myelin, the protective sheath around nerve fibers in the CNS.
  • Molecular Mimicry: The most widely accepted hypothesis. Antigens from an infection or vaccine share structural similarities with CNS myelin proteins (e.g., Myelin Basic Protein [MBP], Myelin Oligodendrocyte Glycoprotein [MOG]). The immune response mounted against the pathogen then cross-reacts with myelin, leading to demyelination.
  • Bystander Activation: An infection triggers inflammation in the CNS, which damages myelin and exposes hidden myelin antigens. This exposure then initiates an autoimmune response.
  • Pathological Features: Histopathology reveals perivascular inflammatory infiltrates (lymphocytes, macrophages) and widespread demyelination without significant axonal loss in the acute phase. Lesions are often poorly demarcated.
• Risk Factors:
  • Recent infection: Particularly viral infections of the respiratory or gastrointestinal tract, typically 2-4 weeks prior to neurological symptom onset. Common pathogens include measles, mumps, rubella, varicella, influenza, Epstein-Barr virus, and Mycoplasma pneumoniae.
  • Recent vaccination: Very rare, but historically associated with some older vaccines (e.g., live attenuated rabies vaccine, smallpox vaccine). Modern vaccines carry an extremely low risk compared to the risk of natural infection.
• Protective Factors: No specific protective factors have been identified for ADEM. General health and timely vaccination against infectious diseases may indirectly reduce the risk of post-infectious ADEM by preventing the primary infection.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Onset is typically acute to subacute, evolving over days to a few weeks.
  • Encephalopathy: A defining feature, present in 50-90% of cases, especially in children. Manifests as altered consciousness (lethargy, confusion, somnolence, stupor, coma), irritability, or behavioral changes.
  • Multifocal neurological deficits: Reflecting widespread CNS involvement.
    • Motor weakness: Hemiparesis, paraparesis, or quadriparesis.
    • Sensory disturbances: Paresthesias, numbness.
    • Cranial neuropathies: Facial palsy, diplopia (due to ocular motor nerve palsies), optic neuritis (unilateral or bilateral visual loss, often painful).
    • Ataxia: Cerebellar involvement leading to impaired coordination and balance.
    • Seizures: Occur in 10-30% of patients, particularly in children.
    • Brainstem symptoms: Dysphagia, dysarthria, nystagmus, often indicating a more severe course.
  • Systemic symptoms: Non-specific symptoms often precede neurological onset (prodrome), including fever, headache, nausea, vomiting, myalgia, and malaise.
• Early Signs: Prodromal symptoms (fever, malaise, headache) followed by rapid onset of neurological symptoms, often beginning with altered mental status, lethargy, or new focal deficits like weakness.
• Advanced Signs: Profound encephalopathy, status epilepticus, severe quadriparesis, respiratory failure requiring ventilatory support, signs of increased intracranial pressure (e.g., papilledema, Cushing's triad). These indicate severe brain involvement and potential for poor outcomes.
• Atypical Presentations:
  • Isolated optic neuritis or transverse myelitis can occur, though typical ADEM involves widespread multifocal lesions.
  • Monophasic course is characteristic, but recurrent forms (MDEM, Biphasic ADEM) or an initial ADEM-like presentation of MOGAD can occur.

Physical Examination

• Inspection:
  • Level of Consciousness: Assess using Glasgow Coma Scale (GCS) or similar scale.
  • General appearance: Signs of recent infection (e.g., rash).
  • Neurological observation: Observe for focal weakness, abnormal movements (e.g., tremor, ataxia), nystagmus, facial asymmetry, signs of meningism (neck stiffness, Kernig/Brudzinski signs, which are often absent or mild in ADEM but should be checked to rule out infectious meningitis/encephalitis).
• Palpation:
  • Muscle tone: May be flaccid in acute phase, later evolving to spasticity.
  • Muscle strength: Assess using Medical Research Council (MRC) scale.
  • Deep Tendon Reflexes: May be diminished or absent acutely, later becoming brisk (hyperreflexia) with Babinski signs indicating upper motor neuron involvement.
• Special Tests:
  • Detailed Neurological Examination: Comprehensive assessment of mental status, cranial nerves, motor system (strength, tone, reflexes), sensory system (light touch, pain, temperature, proprioception, vibration), cerebellar function (coordination, gait), and autonomic function. This is critical to identify multifocal deficits.
  • Fundoscopy: To assess for papilledema (suggesting elevated intracranial pressure) or optic disc swelling/pallor (indicating optic neuritis).

Diagnostic Approach

History Taking

• Key Questions:
  • Preceding events: Detailed inquiry about recent infections (e.g., upper respiratory infection, gastrointestinal illness, rash) or vaccinations in the preceding 2-4 weeks (infections) or 4-6 weeks (vaccinations).
  • Onset and progression: Acute vs. subacute onset of neurological symptoms? How rapidly have they progressed?
  • Nature of neurological symptoms: Specific details about changes in consciousness, focal weakness, sensory changes, visual disturbances, speech difficulties, balance problems, seizures.
  • Prior neurological events: Any history of similar episodes or other neurological symptoms to differentiate from recurrent demyelinating diseases like MS.
  • Developmental history (in children): To assess baseline function.
  • Medication history and allergies.
• Red Flags:
  • Rapidly worsening neurological deficits: Suggests aggressive disease progression.
  • Profound encephalopathy or coma: High risk of respiratory compromise and increased intracranial pressure.
  • Signs of brainstem dysfunction: Dysphagia, dysarthria, gaze palsies, respiratory pattern changes.
  • Status epilepticus: Requires immediate intervention.
  • These warrant immediate neuroimaging and initiation of empiric treatment.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: May show a mild leukocytosis (non-specific).
  • Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP): May be mildly elevated, especially if post-infectious.
  • Serum electrolytes, renal and liver function tests: To rule out metabolic encephalopathy or other systemic causes of neurological dysfunction.
  • Lumbar Puncture (LP) for Cerebrospinal Fluid (CSF) analysis: Essential to rule out infection and differentiate from other inflammatory conditions.
    • Cell count: Often normal or shows mild lymphocytic pleocytosis (<100 cells/µL, usually <50 cells/µL). Higher cell counts should prompt careful consideration of infectious causes.
    • Protein: May be normal or mildly elevated (<100 mg/dL).
    • Glucose: Usually normal.
    • Oligoclonal bands (OCBs): Typically absent in ADEM (present in >90% of MS cases). Their presence, especially if persistent, raises suspicion for MS or another chronic inflammatory CNS disorder.
    • IgG index: Usually normal.
    • Microbiological studies: CSF bacterial culture, viral PCR (e.g., HSV, VZV, enterovirus, West Nile virus), fungal stains, cryptococcal antigen, Lyme serology, VDRL, depending on clinical suspicion, to exclude infectious causes.
  • Infectious serologies: Acute and convalescent titers for suspected preceding infections (e.g., Mycoplasma pneumoniae, measles, mumps, rubella, VZV, EBV, HIV).
• Confirmatory: No specific laboratory test definitively confirms ADEM. Diagnosis is primarily clinical with characteristic MRI findings.
  • Myelin Oligodendrocyte Glycoprotein (MOG) antibody testing: Increasingly important. MOG-IgG positive ADEM represents a distinct entity (MOGAD) with different recurrence risks and potentially different long-term management strategies. Not universally available as a first-line test but highly recommended if MOGAD is suspected or for prognostication.
• Monitoring: Not typically used for ongoing ADEM disease activity after initial diagnosis. Monitoring focuses on recovery, treatment response, and complications. Repeat MRI may be considered if clinical deterioration or new symptoms occur.

Imaging

• Recommended:
  • Brain Magnetic Resonance Imaging (MRI) with contrast: The most critical diagnostic imaging study.
    • Characteristic findings:
      • Multifocal, asymmetric, ill-defined lesions: Typically large (>1-2 cm).
      • Location: Predominantly involve cerebral white matter (subcortical, deep, periventricular, cerebellar), deep gray matter (thalamus, basal ganglia, often bilateral and symmetric thalamic lesions are highly suggestive), brainstem, and sometimes spinal cord.
      • Signal characteristics: T2 hyperintense and FLAIR hyperintense lesions.
      • Enhancement: Variable gadolinium enhancement patterns (patchy, nodular, ring-enhancing, or open-ring enhancement). Enhancement tends to be more prominent in acute lesions.
      • Key differentiators from MS: ADEM lesions are often larger and less well-demarcated than MS lesions, frequently involve deep gray matter (rare in MS), and typically lack the ovoid, periventricular "Dawson's fingers" appearance characteristic of MS. ADEM lesions tend to resolve or shrink significantly over time.
  • Spinal Cord MRI with contrast: If myelopathy (weakness, sensory loss, bladder/bowel dysfunction) symptoms are present. May show large, confluent, T2 hyperintense lesions extending over multiple vertebral segments, often with enhancement.
• Advanced:
  • Diffusion-weighted imaging (DWI) and Apparent Diffusion Coefficient (ADC) maps: Can help characterize acute lesions, showing restricted diffusion in active demyelination or edema.
  • Magnetic Resonance Spectroscopy (MRS): Not routinely used, but can show metabolic changes consistent with demyelination and axonal damage.

Management

Acute Management

• Immediate:
  • Airway, Breathing, Circulation (ABC) stabilization: Crucial, especially in patients with severe encephalopathy or brainstem involvement.
  • Assess for respiratory compromise: Patients with brainstem involvement or profound altered mental status may require intubation and mechanical ventilation.
• Stabilization:
  • Hospitalization: All patients with ADEM require inpatient management, often in a neurology unit or intensive care unit (ICU) for close monitoring.
  • Corticosteroids: High-dose intravenous corticosteroids are the cornerstone of acute ADEM treatment.
    • Methylprednisolone:
      • Adults: 1000 mg/day IV for 3-5 days.
      • Children: 20-30 mg/kg/day IV (maximum 1000 mg/day) for 3-5 days.
    • Followed by a slow oral prednisone taper over 4-6 weeks to prevent relapse as inflammation resolves. Dosing depends on clinical response and patient tolerance.
  • Symptomatic Management:
    • Antiepileptic drugs: For seizures (e.g., levetiracetam, phenytoin).
    • Antipyretics: For fever.
    • Pain control: For headache or neuropathic pain.
    • Management of increased intracranial pressure: If severe cerebral edema or mass effect is present, osmotic agents (e.g., mannitol 0.25-1 g/kg IV, hypertonic saline 3% IV) may be used.
  • Supportive Care:
    • Fluid and electrolyte management: Maintain euvolemia.
    • Nutritional support: Nasogastric tube feeding or parenteral nutrition for patients unable to swallow or with prolonged altered consciousness.
    • Prevention of complications: Deep vein thrombosis (DVT) prophylaxis (heparin/LMWH) in immobilized patients, pressure ulcer prevention, bladder management, bowel care.
• Emergency: Management of neurological emergencies such as status epilepticus, severe cerebral edema with impending herniation, or acute respiratory failure due to brainstem involvement. These require rapid assessment and intervention in an ICU setting.

Chronic Management

• Pharmacological:
  • Second-line immunomodulatory therapies: Considered if there is an inadequate response to corticosteroids (no improvement or worsening after 48-72 hours) or if steroids are contraindicated.
    • Intravenous Immunoglobulin (IVIG):
      • Dose: 400 mg/kg/day IV for 5 days.
      • Mechanism: Blocks antibody-mediated damage, modulates immune cell function.
    • Plasma Exchange (PLEX):
      • Procedure: Typically 5-7 exchanges over 7-14 days.
      • Mechanism: Removes circulating antibodies and inflammatory mediators.
      • Indications: Reserved for severe, rapidly progressive cases unresponsive to high-dose steroids and/or IVIG.
  • Long-term Immunosuppression: Generally not indicated for classic monophasic ADEM. However, in cases of recurrent ADEM (MDEM) or MOG-IgG positive ADEM (MOGAD), long-term immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, rituximab) may be considered, often under the guidance of a neuroimmunologist.
• Non-pharmacological:
  • Rehabilitation: Essential for optimizing recovery and minimizing long-term disability.
    • Physical therapy: To improve motor strength, balance, coordination, and gait.
    • Occupational therapy: To regain independence in activities of daily living.
    • Speech and language therapy: For dysarthria, dysphagia, or cognitive-communicative deficits.
    • Neuropsychological rehabilitation: For cognitive impairment, behavioral changes, or emotional difficulties.
  • Psychological Support: For patients and families to cope with the challenges of illness and recovery.
  • Education: Providing comprehensive information about ADEM, its prognosis, potential complications, and recurrence risk.
• Monitoring:
  • Clinical follow-up: Regular neurological assessments to monitor recovery, identify residual deficits, and detect any new symptoms or recurrence.
  • Repeat MRI: Not routinely recommended unless there is clinical deterioration, new symptoms, or diagnostic uncertainty. If done, it can assess resolution of acute lesions or appearance of new lesions that might suggest an alternative diagnosis (e.g., MS).

Treatment Algorithms

• First-Line:
  1. High-dose IV Methylprednisolone: 20-30 mg/kg/day (max 1g/day) IV for 3-5 days.
  2. Followed by a slow oral corticosteroid taper over several weeks.
• Second-Line: If no significant clinical improvement within 48-72 hours of IV steroids, or for severe/rapidly progressive disease:
  1. IV Immunoglobulin (IVIG): 400 mg/kg/day for 5 days. (Often preferred in children or when PLEX is not readily available).
  2. Plasma Exchange (PLEX): 5-7 exchanges over 7-14 days. (Often considered for more severe, rapidly progressive, or steroid-refractory cases).
• Refractory Cases:
  • Combination therapy (e.g., IVIG followed by PLEX, or IVIG concurrently with PLEX) may be considered.
  • Cyclophosphamide: Rarely used, for highly refractory or fulminant cases (e.g., AHLE) under specialist guidance due to significant side effects.
  • For recurrent forms (MDEM) or MOGAD, long-term immunosuppression (e.g., azathioprine, mycophenolate mofetil, rituximab) might be initiated by a neuroimmunologist.

Complications

• Common:
  • Residual neurological deficits: Including mild motor weakness, ataxia, sensory symptoms, or subtle cognitive impairment (e.g., attention, memory, executive function), and fatigue. Up to 10-30% of patients may have some long-term deficits.
  • Spasticity: Can develop as a long-term consequence of upper motor neuron involvement.
• Serious:
  • Respiratory failure: Due to brainstem involvement (central hypoventilation) or severe weakness.
  • Status epilepticus: Prolonged or recurrent seizures that can cause further brain damage.
  • Increased intracranial pressure / Cerebral edema: Leading to brain herniation and death if not managed promptly.
  • Acute Hemorrhagic Leukoencephalitis (AHLE): A fulminant, rapidly progressive, and often fatal variant of ADEM with widespread brain necrosis and hemorrhage.
  • Secondary infections: Aspiration pneumonia (due to dysphagia), urinary tract infections, sepsis.
  • Thromboembolic events: Deep vein thrombosis (DVT) and pulmonary embolism (PE) in immobilized patients.
• Long-term:
  • Chronic neurological disability: Varying degrees of motor, sensory, or cognitive impairment.
  • Secondary epilepsy: In a small percentage of patients.
  • Visual impairment: If optic neuritis was severe or recurrent.
  • Neuropsychiatric sequelae: Including mood disorders (depression, anxiety), behavioral changes, or attention deficit issues, particularly in children.
  • Risk of misdiagnosis as MS: While ADEM is typically monophasic, some cases initially diagnosed as ADEM, especially those with positive OCBs or atypical MRI findings, may later be reclassified as a first clinical attack of MS. Conversely, a proportion of MOG-IgG positive ADEM cases may recur (MDEM or MOGAD).

Prognosis

• Factors Affecting Outcome:
  • Age: Younger children generally have a better prognosis and higher rates of complete recovery compared to adults.
  • Severity of initial attack: Milder cases tend to have better outcomes. Profound encephalopathy, brainstem involvement, and severe motor deficits are associated with worse prognosis.
  • Rapid initiation of treatment: Early and aggressive immunotherapy (corticosteroids) is associated with better recovery.
  • Imaging findings: Extensive lesion burden, brainstem involvement, and hemorrhagic components (AHLE) are associated with poorer outcomes.
  • MOG-antibody status: MOG-IgG positive ADEM tends to have a generally favorable prognosis for recovery from acute attacks but has a higher risk of recurrence (MDEM or MOGAD) compared to MOG-IgG negative ADEM.
• Survival:
  • The overall prognosis for ADEM is generally good.
  • Most patients (50-80%) achieve a full or near-full neurological recovery within weeks to months.
  • Mortality rates are low, typically 1-5%. However, mortality can be as high as 30% in severe cases or the fulminant AHLE variant.
• Quality of Life:
  • While many recover fully, a significant minority (10-30%) may experience residual neurological deficits that can impact their long-term quality of life, including motor weakness, ataxia, cognitive impairment, or behavioral issues.
  • Rehabilitation plays a crucial role in maximizing functional recovery and improving quality of life.

Prevention

• Primary Prevention:
  • Vaccination: Timely and appropriate vaccination against common infectious diseases (e.g., measles, mumps, rubella, influenza) may indirectly reduce the risk of post-infectious ADEM by preventing the primary infection. The risk of ADEM following vaccination is exceedingly rare and far outweighed by the benefits of preventing the target infectious disease.
  • General hygiene: Reducing exposure to infections through good hand hygiene and avoiding sick individuals.
• Secondary Prevention:
  • Early diagnosis: Prompt recognition of ADEM symptoms and timely diagnostic workup are critical to allow for early initiation of immunotherapy.
  • Aggressive acute treatment: Immediate and appropriate treatment with corticosteroids (and second-line therapies if needed) can limit neurological damage and improve the chances of full recovery.
• Tertiary Prevention:
  • Rehabilitation: Comprehensive physical, occupational, and speech therapy to minimize long-term disability and optimize functional outcomes.
  • Long-term follow-up: Regular neurological assessments to monitor for residual deficits, provide support, and identify any rare recurrences or alternative diagnoses.

Special Populations

• Pediatric:
  • ADEM is more prevalent in children, with a mean age of 5-8 years.
  • Encephalopathy is a more prominent and common feature in pediatric ADEM.
  • Children generally tend to have a better prognosis and higher rates of complete recovery than adults.
  • Immunotherapy dosages (e.g., methylprednisolone) are typically weight-based.
• Geriatric:
  • ADEM is less common in older adults.
  • Diagnosis can be challenging due to overlapping symptoms with other neurological conditions or comorbidities.
  • Outcomes may be less favorable due to lower neurological reserve, increased susceptibility to complications (e.g., infections, DVT), and comorbidities that may limit aggressive treatment.
  • Careful consideration of steroid side effects (e.g., hyperglycemia, hypertension, osteoporosis, increased infection risk) is paramount.
• Pregnancy:
  • ADEM during pregnancy is rare.
  • High-dose intravenous corticosteroids are generally considered safe during pregnancy, particularly after the first trimester.
  • IVIG is also considered safe in pregnancy.
  • PLEX may be considered in severe, refractory cases.
  • Treatment decisions should involve a careful risk-benefit assessment for both mother and fetus, ideally with multidisciplinary input.
• Comorbidities:
  • The presence of pre-existing medical conditions (e.g., diabetes mellitus, hypertension, cardiovascular disease, immunocompromised states) requires careful management and adjustment of treatment protocols.
  • High-dose corticosteroids can exacerbate pre-existing conditions, requiring close monitoring and supportive therapies (e.g., insulin for hyperglycemia, antihypertensives).
  • Immunosuppressive therapies can increase the risk of infection in already vulnerable patients.

Clinical Pearls

• Diagnostic:
  • Encephalopathy is key: Always consider ADEM in patients presenting with acute, multifocal neurological deficits and encephalopathy (altered mental status), especially if preceded by an infection. This feature helps differentiate it from a first attack of MS, where encephalopathy is rare.
  • MRI is crucial: Characteristic MRI findings (large, ill-defined, multifocal lesions, often involving deep gray matter, no MS-typical Dawson's fingers) are vital for diagnosis and differentiation.
  • CSF OCBs: The absence of oligoclonal bands in CSF strongly supports an ADEM diagnosis over MS. If OCBs are present, especially if persistent, consider MS or other inflammatory conditions and closer follow-up.
  • MOG-IgG: Consider testing for MOG-IgG antibodies in all suspected ADEM cases, as MOGAD (which can present as ADEM) is a distinct entity with implications for recurrence risk and potential long-term management.
• Treatment:
  • Do not delay treatment: If clinical suspicion for ADEM is high, initiate high-dose corticosteroids promptly after obtaining initial diagnostic tests (MRI, LP). Delaying treatment can lead to worse outcomes.
  • Aggressive initial therapy: High-dose IV methylprednisolone is the first-line treatment. Be prepared to escalate to IVIG or PLEX if there is no significant response within 48-72 hours or if the disease is rapidly progressing.
  • Rehabilitation is vital: Emphasize the importance of early and sustained rehabilitation to maximize recovery, even in cases of severe initial disability.
• Pitfalls:
  • Misdiagnosis as MS: This is a common pitfall. Misdiagnosis can lead to inappropriate long-term immunomodulatory therapy. Careful attention to encephalopathy, MRI features, and CSF OCBs is essential. Follow-up MRI and clinical reassessment are crucial, especially if atypical features suggest MS.
  • Underestimating severity: ADEM can be a life-threatening condition, particularly the AHLE variant. Close monitoring for respiratory compromise, increased intracranial pressure, and seizures is necessary.
  • Attributing symptoms solely to infection: Do not mistake the neurological manifestations of ADEM for direct effects of the preceding infection. ADEM is an immune-mediated complication.

Recent Updates

• Guidelines: The emergence and recognition of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) as a distinct clinical entity have significantly impacted the diagnostic and management approach to ADEM. International consensus criteria for MOGAD (e.g., 2023 international consensus criteria for MOGAD) are guiding clinical practice. Many cases previously diagnosed as recurrent ADEM (MDEM) are now reclassified as MOGAD.
• Evidence: Ongoing research highlights the importance of specific autoantibodies (like MOG-IgG) in delineating different inflammatory demyelinating syndromes, leading to more precise diagnoses and tailored treatments. There is increasing evidence suggesting that MOG-IgG positive patients have a higher recurrence rate compared to MOG-IgG negative patients, necessitating careful consideration of long-term immune suppression in some cases.
• Controversies: Debates persist regarding the optimal duration and tapering schedule of corticosteroids. The role and timing of long-term immunosuppression for MOG-IgG positive ADEM, especially after a first attack, remain areas of active research and ongoing discussion among experts. The precise differentiation between ADEM, MOGAD, and early MS in challenging cases continues to evolve.

Key References

• Guidelines:
  • International Consensus Criteria for MOG-Antibody Disease (MOGAD): Recent publications (e.g., Wingerchuk et al., The Lancet Neurology, 2023) provide updated diagnostic criteria and recommendations for this evolving field.
  • Consensus guidelines for the treatment of inflammatory demyelinating diseases: Various professional organizations (e.g., European Academy of Neurology, American Academy of Neurology) periodically update guidelines.
• Studies:
  • Landmark studies on ADEM clinical course and outcomes: Consult prominent neurological journals (e.g., Neurology, Brain, Annals of Neurology) for foundational and recent research on ADEM.
  • Studies on MOG-IgG seroprevalence and clinical phenotypes: Research exploring the spectrum of MOGAD and its distinct characteristics compared to other demyelinating diseases.
• Reviews:
  • Comprehensive reviews in major medical textbooks:
    • UpToDate (online clinical reference)
    • Harrison's Principles of Internal Medicine
    • Merrit's Neurology
    • Bradley's Neurology in Clinical Practice
  • Review articles in peer-reviewed journals: Search for recent review articles on ADEM and MOGAD in journals like The Lancet Neurology, Nature Reviews Neurology, and Seminars in Neurology.